Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2018-04-19 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
2017年度独立董事述职报告（徐爱民）
Board/Management Information Classification · 95% confidence The document is titled '2017 年度独立董事述职报告' which translates to '2017 Annual Independent Director's Work Report'. It details the independent director's participation in board meetings, opinions on various company matters, committee work, investigations, investor protection efforts, and training during the year 2017. The content focuses on the independent director's duties and activities rather than financial results or audit opinions. It is a report on board/management activities and governance rather than a financial report or announcement. Therefore, the document fits best under Board/Management Information (MANG). The document length is 3309 characters, which is not very short, and it contains substantive content rather than just an announcement or certification, so it is not RPA or RNS.
2018-04-19 Chinese
2017年度独立董事述职报告（吴育辉）
Board/Management Information Classification · 95% confidence The document is titled '2017年度独立董事述职报告' which translates to '2017 Annual Independent Director's Work Report'. It is a detailed report by an independent director about their duties, attendance at board and shareholder meetings, opinions given, committee work, investigations, investor protection efforts, training, and other matters during the 2017 fiscal year. The content focuses on the director's role and activities rather than financial results or audit opinions. It is not an annual report (10-K), audit report (AR), or management report (MDA). It is a specialized report related to board/management information, specifically the independent director's report on their duties and opinions. Therefore, the best fitting category is Board/Management Information (MANG). The document length is 3245 characters, which is substantive and not a mere announcement or certification, so it is not RPA or RNS. Confidence is high given the clear nature of the document.
2018-04-19 Chinese
独立董事关于第一届董事会第十九次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors providing prior approval opinions on matters to be discussed at the 19th meeting of the first board of directors. It references regulatory guidelines related to independent directors and audit firm reappointment for the 2018 fiscal year, as well as anticipated related party transactions. The document is not a full audit report or annual report but rather an opinion or approval statement related to board meeting agenda items. It does not contain financial statements or detailed financial data. This type of document fits best under Board/Management Information (MANG), as it concerns board meeting matters and director opinions on company governance issues.
2018-04-19 Chinese
关于2018年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Shenzhen BGI Genomics Co., Ltd. regarding the expected daily related party transactions for the year 2018. It includes extensive financial data, descriptions of related parties, transaction categories, pricing policies, and approvals by the board. The content focuses on the company's related party transactions, their necessity, pricing, and compliance with regulatory requirements. It is not a full annual report, audit report, earnings release, or any other financial statement. It is a regulatory announcement about related party transactions, which is a common type of regulatory filing in Chinese listed companies. The document is lengthy (15,000 characters) and contains substantive data and explanations about related party transactions, but it is not a financial report per se. Given the nature and content, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2018-04-19 Chinese
关于控股子公司中标长沙市健康民生项目的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Shenzhen BGI Co., Ltd. regarding its controlling subsidiary winning a government procurement project for gene testing services. It details the project, contract terms, expected financial impact, and risk warnings. The document is relatively short (1817 characters) and does not contain financial statements or detailed financial analysis. It is a specific business update about a contract award, not a financial report, earnings release, or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Capital Update. It is a regulatory announcement about a contract win, which fits best under Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2018-04-12 Chinese
2018年第一季度业绩预告
Earnings Release Classification · 95% confidence The document is titled as a '2018年第一季度业绩预告' which translates to '2018 First Quarter Earnings Forecast'. It provides estimated financial performance for the period January 1, 2018 to March 31, 2018, including expected net profit growth percentages and explanations for the changes. It explicitly states that the forecast is unaudited and that detailed financial data will be disclosed in the actual first quarter report. The document is short (1082 characters) and serves as an earnings forecast rather than a full financial report. This matches the definition of an Earnings Release (ER), which is an initial announcement of quarterly/periodical financial results with key highlights only. Q1 2018
2018-04-09 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.